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ized, double-blind studies of the efficacy of amisulpride in patients 
with schizophrenia spectrum disorders and found the same results. 
More improvement occurs in the first few days than in any later 
period of equal duration (Leucht et al., 2005). These findings are in 
contrast to the traditional held belief that the onset of antipsychotic 
action is delayed and takes 2-3 weeks before the onset of therapeutic 
benefits is produced (Gelder et al., 2000).
This change in our clinical understanding demands a re-exami-
nation of the currently available animal models of antipsychotic 
drugs. Many models rely on the acute effects of antipsychotic treat-
ment, including amphetamine-induced hyperlocomotion, the cat-
alepsy and paw test to prepulse inhibition, latent inhibition, and 
social interaction (Arnt, 1982; Ellenbroek et al., 1987; Hoffman and 
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Abstract
Clinical obervations indicate that antipsychotic action starts early and increases in magnitude with repeated treatment. Animal 
models that faithfully capture this time course of action are few. Inhibition of hyperlocomotion induced by amphetamine or 
phencyclidine has been widely used as a screening tool for the antipsychotic activity of a drug. We thus investigated whether 
repeated antipsychotic treatment could produce an early-onset and progressively increased antagonistic effect on amphetamine 
or phencyclidine-induced hyperlocomotion as a way of assessing the validity of such models in capturing time course of antip-
sychotic action. One each of the five consecutive test days, different groups of rats (n = 6-7/group) received an initial injection of 
either haloperidol (0.01-0.10 mg/kg, sc), clozapine (5-20.0 mg/kg, sc), olanzapine (1.0 mg/kg, sc), chlordiazepoxide (10.0 mg/
kg, ip) or vehicle (sterile water, sc) 30 min prior to a second injection of either amphetamine (1.5 mg/kg, sc) or phencyclidine (3.2 
mg/kg, sc). Motor activity was subsequently monitored for 60 min after amphetamine or phencyclidine treatment. Repeated 
treatment of haloperidol, clozapine, or olanzapine progressively potentiated inhibition on repeated phencyclidine-induced 
hyperlocomotion and prolonged this action over the five consecutive days. In contrast, antipsychotic inhibition on repeated 
amphetamine-induced hyperlocomotion was gradually attenuated and shortened. Repeated treatment of chlordiazepoxide, a 
benzodiazepine anxiolytic, retained its inhibition on amphetamine-induced hyperlocomotion, but had no effect on phencycli-
dine-induced one. These results suggest that repeated phencyclidine-induced hyperlocomotion model based on repeated antip-
sychotic treatment regimen is capable of capturing the progressive increase pattern of antipychotic treatment seen in the clinic 
and differentiating antipsychotics from anxiolytics; thus it may serve as a better model for the investigation of the neurobiolog-
ical mechanisms of action of antipsychotic drugs and delineating the pathophysiology of schizophrenia.
1. Introduction
Recent years have witnessed a growing number of clinical studies 
suggesting that antipsychotic action starts early and increases in mag-
nitude with repeated treatment (Agid et al., 2003, 2006; Emsley et al., 
2006; Glick et al., 2006; Kapur et al., 2005; Leucht et al., 2005; Raedler 
et al., 2007). For example, Agid et al. (2003) examined 42 double-blind, 
comparator-controlled studies (> 7000 patients) using a meta-analy-
sis technique. They found that psychotic symptoms improved within 
the first week of treatment and showed a progressive improvement 
over subsequent weeks, with the overall pattern of improvement 
approximating an exponential curve. Leucht et al. (2005) analyzed a 
large homogeneous database of original patient data from 7 random- 
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tilled water. Haloperidol, clozapine, olanzapine, amphetamine and 
phencyclidine were administered subcutaneously, whereas chlordi-
azepoxide was administered intraperitoneally.
2.3. Locomotor activity apparatus
Sixteen activity boxes were housed in a quiet room. The boxes 
were 48.3 cm × 26.7 cm × 20.3 cm transparent polycarbonate cages, 
which were similar to the home cages but were each equipped with a 
row of 6 photocell beams (7.8 cm between two adjacent photobeams) 
placed 3.2 cm above the floor of the cage. A computer detected the 
disruption of the photocell beams and recorded the number of beam 
breaks. All experiments were run during the light cycle.
2.4. Experiment 1: effects of repeated haloperidol and clozapine treatment 
on amphetamine-induced hyperlocomotion
In this experiment, we examined the effects of repeated haloperi-
dol and clozapine treatment on amphetamine-induced hyperloco-
motion. We chose three doses of haloperidol (0.01, 0.05 and 0.10 mg/
kg) and clozapine (5, 10, and 20 mg/kg) which cover subclinical, 
optimal clinical, and supra-clinical doses based on the dopamine D2 
occupancy data (50%-75% occupancy) (Kapur et al., 2003a). Also, at 
the medium and high doses, both haloperidol and clozapine selec-
tively disrupt avoidance responding—a validated behavioral index 
of antipsychotic activity (Li et al., 2004). The dose for amphetamine 
was 1.5 mg/kg, which is the common dose used in the literature 
(Arnt, 1995; Natesan et al., 2006; Sills et al., 2000).
2.5. Experimental procedure
Forty-eight rats were randomly assigned to one of eight groups (n 
= 6/group): vehicle (water) + vehicle (saline, SAL), vehicle (water) 
+ amphetamine, haloperidol (0.01 mg/kg) + amphetamine, halo-
peridol (0.05 mg/kg) + amphetamine, haloperidol (0.10 mg/kg) 
+ amphetamine, clozapine (5.0 mg/kg) + amphetamine, clozap-
ine (10.0 mg/kg) + amphetamine, and clozapine (20.0 mg/kg) + 
amphetamine. After two days of habituation to the testing room 
and the testing boxes (30 min/day for 2 days), on day 1, rats first 
received one of the following seven subcutaneous injections: vehi-
cle (sterile water), haloperidol 0.01, 0.05, or 0.10 mg/kg, or clozap-
ine 5.0, 10.0, or 20.0 mg/kg. They were then immediately placed 
in locomotor activity boxes for 30 min. At the end of the 30-min 
period, rats were taken out and injected with either vehicle (sc) 
or amphetamine (1.5 mg/kg, sc) and placed back in the boxes for 
another 60 min. Locomotor activity (number of photobeam breaks) 
was measured in 5 min intervals throughout the entire 90-min test-
ing session. This procedure was repeated for another 4 days (a total 
of 5 testing days).
2.6. Experiment 2: effects of repeated haloperidol and clozapine treatment 
on phencyclidine-induced hyperlocomotion 
Experiment 2 examined the effects of repeated haloperidol and 
clozapine treatment on phencyclidine-induced hyperlocomotion. 
The basic procedure was identical to that of Experiment 1 with the 
exception that phencyclidine (3.2 mg/kg, sc) was used. This dose of 
phencyclidine is shown to induce a robust hyperlocomotion effect 
without causing severe stereotypy (Gleason and Shannon, 1997; 
Kalinichev et al., 2008).
2.7. Experiment 3: effects of repeated olanzapine and chlordiazepoxide treat-
ment on amphetamine or phencyclidine-induced hyperlocomotion
Experiment 3 examined the effects of repeated olanzapine and 
chlordiazepoxide treatment on amphetamine or phencyclidine 
induced hyperlocomotion. Forty-eight rats were randomly assigned 
to one of seven groups (n = 6/vehicle group, n = 7 for other groups): 
vehicle (water, sc or ip) + vehicle (saline, sc), vehicle (water, sc)  + 
Donovan, 1995; Sams-Dodd, 1999; Swerdlow et al., 2000; Weiner, 
2003). Because of the limitation of acute treatment regimen, none of 
these models provides a relevant model of time course of antipsy-
chotic effect. On the other hand, models that have used chronic treat-
ment regimens, such as “depolarization block” (Grace and Bunney, 
1986), antipsychotic-induced Fos expression (Robertson and Fibiger, 
1992), social behavior (Sams-Dodd, 1998), or the chronic prepulse 
inhibition model (Andersen and Pouzet, 2001), have often examined 
behavioral or physiological changes after a certain period of treat-
ment has elapsed (e.g., ~21 days after the first drug administration), 
instead of during the chronic treatment period. Thus, they are lim-
ited in tracking changes that occur during the treatment period.
We recently developed a rat conditioned avoidance responding 
model based on a repeated treatment regimen and examined its 
validity in modeling the time course of antipsychotic effect (Li et al., 
2007). We found that rats repeatedly treated with haloperidol, olan-
zapine, or risperidone exhibited a decrease in avoidance responding 
starting on the first day of treatment. Over the seven daily test ses-
sions, their avoidance responding displayed a progressive, across-
session decline, which recovered after treatment was stopped. In 
contrast, rats treated with chlordiazepoxide or vehicle maintained 
a high level of avoidance responding throughout the entire testing 
period. Thus the repeated treatment conditioned avoidance respond-
ing model seems capable of mimicking several key features of clin-
ical effects of antipsychotics, such as early-onset, progressive accu-
mulation, asymptote, and drug-discontinuation relapse.
The present study represents another attempt to develop clinically 
relevant animal models of antipsychotic activity that capture impor-
tant hallmarks of clinical features of antipsychotic treatment along 
the time course of antipsychotic treatment in the clinic. The objec-
tive was to investigate whether repeated antipsychotic treatment, 
as opposed to anxiolytic treatment, could produce an early-onset 
and progressively increased inhibitory effect on the amphetamine 
or phencyclidine-induced hyperlocomotion. Both amphetamine 
and phencyclidine-induced hyperlocomotion models are commonly 
used as screening tools for the detection of antipsychotic activity. 
When given acutely, all antipsychotics inhibit hyperlocomotor activ-
ity induced by acute administrations of amphetamine or phency-
clidine (Arnt, 1995; Gleason and Shannon, 1997). However, little is 
known about the effects of repeated antipsychotic treatment on the 
motor activity induced by repeated amphetamine or phencyclidine 
treatment.
2. Materials and methods
2.1. Animals
A total of 144 male Sprague-Dawley rats (226-250 g upon arrival, 
Charles River, Portage, MI) were used. They were housed two per 
cage, in 48.3 cm × 26.7 cm × 20.3 cm transparent polycarbonate cages 
under 12-h light/dark conditions (light on between 6:30 am and 
6:30 pm). Room temperature was maintained at 21±1° C with a rela-
tive humidity of 55-60%. Food and water were available ad libitum. 
Animals were allowed at least one week of habituation to the ani-
mal facility before being used in experiments. All procedures were 
approved by the Institutional Animal Care and Use Committee at 
the University of Nebraska-Lincoln.
2.2. Drugs
The injection solutions of haloperidol (5 mg/ml ampoules, Sabex 
Inc. Boucheville, Quebec, Canada) and chlordiazepoxide (Sigma-
Aldrich, St. Louis, MO) were obtained by mixing drugs with sterile 
water. The injection solutions of d-amphetamine sulfate (Sigma-RBI) 
and phencyclidine hydrochloride (gift from National Institute on 
Drug Abuse Chemical Synthesis and Drug Supply Program) were 
obtained by mixing drugs with 0.9% saline. Clozapine (gift from the 
NIMH drug supply program) and olanzapine (Toronto Research 
Chemical Inc., Canada) were dissolved in 1.5% glacial acetic acid dis-
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of six antipsychotic-treated groups showed a significant upward 
increase in motor activity (all Ps < 0.05, except the haloperidol 0.01 
mg/kg group, F(4,20) = 1.707, P = 0.188), indicating that the inhibi-
tory effect of haloperidol and clozapine was gradually weakened by 
repeated drug administration.
This attenuation effect was most apparent with the highest dose 
of haloperidol (0.10 mg/kg) and clozapine (20 mg/kg) (see Figure 
1). For example, haloperidol at 0.10 mg/kg reduced amphetamine-
induced hyperlocomotion by 77% on day 1, but only 54% on day 5. 
Similarly, clozapine at 20.0 mg/kg reduced amphetamine-induced 
hyperlocomotion by 64% on day 1, but only 31% on day 5. Percent 
inhibition was calculated using this formula:
3.1.3. Repeated haloperidol and clozapine treatment shortened the time 
course of the inhibitory action on amphetamine-induced hyperlocomotion
Figure 2 shows the time course (measured in 5-min blocks over 
the 60-min period after amphetamine injection) of the effects of halo-
peridol and clozapine treatment on amphetamine-induced hyperlo-
amphetamine (1.5 mg/kg, sc), vehicle (water, sc) + phencyclidine 
(3.2 mg/kg, sc), olanzapine (1.0 mg/kg, sc) + amphetamine, olanzap-
ine (1.0 mg/kg, sc) + phencyclidine, chlordiazepoxide (10.0 mg/kg, 
ip) + amphetamine, and chlordiazepoxide (10.0 mg/kg, ip) + phen-
cyclidine. The basic procedure was identical to that of Experiment 1. 
We chose olanzapine 1.0 mg/kg dose because this is a clinically rel-
evant dose in terms of its ability to disrupt conditioned avoidance 
responding (Li et al., 2007), as well as to give rise to ~70% striatal D2 
occupancy (Kapur et al., 2003b). We included 10.0 mg/kg chlordiaz-
epoxide as a pharmacological control. This dose of chlordiazepox-
ide is ineffective in disrupting avoidance responding (Li et al., 2004, 
2007; Mead et al., 2008), but it is effective in several aversively condi-
tioned paradigms, such as Pavlovian fear conditioning and passive 
avoidance responding (Burghardt et al., 2004; Joordens et al., 1998; 
Klint, 1991; Mead et al., 2008).
2.8. Statistical analysis
Motor activity data from the five consecutive drug test days were 
expressed as mean values ± S.E.M. and analyzed using a facto-
rial repeated measures ANOVA with the between-subjects factor 
being the treatment conditions (“Treatment,” e.g. 3 doses of halo-
peridol vs. vehicle), and the within-subject factor being the test days 
(“Days,” e.g. day 1 test, day 2 test, etc.), followed by Post-hoc Tukey 
tests to examine two-group difference. Motor activity data from each 
daily test were also analyzed using a factorial repeated measures 
ANOVA with the between-subjects factor being the treatment con-
ditions (“Treatment,” e.g. 3 doses of haloperidol vs. vehicle), and the 
within-subject factor being the 5-min time block (“Block,” e.g. block 
for 60 min after amphetamine or phencyclidine injection). If neces-
sary, one-way ANOVA was used to identify two-group difference. 
A conventional two-tailed level of significance at the 5% level was 
required.
3. Results
3.1. Experiment 1: effects of repeated haloperidol and clozapine treatment 
on amphetamine-induced hyperlocomotion
3.1.1. Acute haloperidol and clozapine treatment dose-dependently inhib-
ited the hyperlocomotion induced by amphetamine
Figure 1 shows the mean locomotor activity of the eight groups 
of rats during the 60-min test period after vehicle or amphetamine 
injection across the five test days. On day 1, acute haloperidol and 
clozapine treatment dose-dependently inhibited the hyperlocomo-
tion induced by amphetamine. One-way ANOVA revealed that 
there was a significant main effect of “Treatment”( F(7,47) = 16.368, P < 
0.001). Post-hoc Tukey tests showed that in comparison to the vehi-
cle treatment, amphetamine produced a robust increase in motor 
activity (P < 0.001). This amphetamine effect was significantly atten-
uated by haloperidol at 0.05 mg/kg (P = 0.006) and 0.10 mg/kg (P < 
0.001) and clozapine at 10.0 and 20.0 mg/kg (P < 0.001). Low dose of 
haloperidol (0.01 mg/kg) and clozapine (5.0 mg/kg) did not signifi-
cantly inhibit amphetamine-induced hyperlocomotion (haloperidol 
0.01 mg/kg, P = 0.999; clozapine 5.0 mg/kg, P < 0.148 vs. the vehicle 
+ amphetamine group).
3.1.2. Repeated haloperidol and clozapine treatment attenuated the inhibi-
tion on the amphetamine-induced hyperlocomotion across days
Two-way repeated measures ANOVA with the treatment condi-
tions as the between-subjects variable and testing days as the within-
subjects variable revealed a significant main effect of “Treatment” 
(F(7,40) = 13.074, P < 0.001), a significant main effect of “Days” (F(4,160) 
= 16.701, P < 0.001), and “Treatment” × “Days” interaction (F(28,160) = 
1.965, P = 0.005). This interaction effect was attributed to the across-
session change in the effects of repeated haloperidol and clozapine 
treatments on amphetamine-induced hyperlocomotion. Over the 
5 test days, repeated amphetamine treatment did not significantly 
increase motor activity (F(4,20) = 1.513, P = 0.236). However, five out 
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the amphetamine injection and lasted for the remainder of the test 
session (all Ps < 0.001 in comparison to the vehicle + amphetamine 
group). However, on day 5, although its inhibitory effect also started 
at the 10-min point (P = 0.001), the inhibition only lasted about 40 
min as the haloperidol 0.10 mg/kg group no longer differed signifi-
cantly from the vehicle + amphetamine group on the last two 5-min 
blocks (all Ps < 0.05). Similarly for clozapine, on day 1, clozapine 10 
mg/kg and 20 mg/kg inhibited amphetamine-induced hyperloco-
motion starting at the 10-min point (all Ps < 0.001) and lasted for 
the remainder of the test session (all Ps < 0.04 one-tailed in compar-
ison to the vehicle + amphetamine group). In contrast, on day 5, the 
two clozapine groups did not differ significantly from the vehicle + 
amphetamine group in any 5-min blocks except one (all Ps < 0.05 
except at the 45-min point, P = 0.03 for clozapine 10 mg/kg group vs. 
the vehicle + amphetamine).
3.2. Experiment 2: effects of repeated haloperidol and clozapine treatment 
on phencyclidine-induced hyperlocomotion
3.2.1. Acute haloperidol and clozapine treatment dose-dependently inhib-
ited the hyperlocomotion induced by phencyclidine
Figure 3 shows the mean locomotor activity of the eight groups of 
rats during the 60-min period after vehicle or phencyclidine injec-
tion across the five test days. On day 1, acute haloperidol and clozap-
ine treatment dose-dependently inhibited phencyclidine-induced 
hyperlocomotion. One-way ANOVA revealed that there was a sig-
nificant main effect of “Treatment” (F(7,47) = 27.203, P < 0.001). Post-
hoc Tukey tests showed that in comparison to the vehicle treatment, 
comotion on the first and last day of drug testing (excluding the 
vehicle + vehicle group). It appears that with repeated treatment, 
haloperidol and clozapine shortened its inhibition on amphetamine-
induced hyperlocomotion. For example, on day 1, the inhibitory 
effect of haloperidol 0.10 mg/kg started at the 10-min point after 
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that in comparison to the vehicle treatment, amphetamine produced 
a robust increase in motor activity (P < 0.001). Olanzapine at 1.0 mg/
kg and chlordiazepoxide at 10.0 mg/kg significantly inhibited the 
phencyclidine produced a robust increase in motor activity (P < 
0.001). This phencyclidine effect was significantly attenuated by 
haloperidol at 0.05 mg/kg (P = 0.016) and 0.10 mg/kg (P = 0.002) 
and clozapine at all three doses (all Ps < 0.002). Low dose of halo-
peridol (0.01 mg/kg) did not significantly inhibit phencyclidine-
induced hyperlocomotion (haloperidol 0.01 mg/kg, P = 1.00).
3.2.2. Repeated haloperidol and clozapine treatment potentiated the inhibi-
tion on phencyclidine-induced hyperlocomotion across days
Two-way repeated measures ANOVA with treatment conditions 
as the between-subjects variable and test days as the within-subjects 
variable revealed a significant main effect of “Treatment” (F(7,40) = 
44.577, P < 0.001), a significant main effect of “Days” (F(4,160) = 5.079, 
P = 0.001), and “Treatment” × “Days” interaction (F(28,160) = 4.035, P 
< 0.001). This interaction effect was attributed to the across-session 
change in the effects of repeated haloperidol and clozapine treat-
ment on phencyclidine-induced hyperlocomotion. Throughout the 
5 test days, repeated phencyclidine treatment significantly increased 
motor activity (F(4,20) = 4.080, P = 0.014), indicating a phencyclidine-
induced behavioral sensitization. Despite this, repeated treatment 
of haloperIdol and clozapine progressively strengthened their abil-
ity to inhibit phencyclidine-induced hyperlocomotion. Across the 5 
drug test days, four out of six antipsychotic-treated groups showed 
a significant decrease in motor activity (all Ps < 0.05, except the halo-
peridol 0.01 mg/kg group, F(4,20) = 0.804, P = 0.537 and clozapine 10 
mg/kg group, F(4,20) = 0.523, P = 0.720). This potentiated inhibition 
was most apparent in the haloperidol 0.10 mg/kg group and clo-
zapine 5.0 mg/kg group. For example, haloperidol at 0.10 mg/kg 
reduced phencyclidine-induced hyperlocomotion by 42% on day 1, 
but 89% on day 5. Similarly, clozapine at 5.0 mg/kg reduced phen-
cyclidine-induced hyperlocomotion by 42% on day 1, but up to 66% 
on day 5.
3.2.3. Repeated haloperidol and clozapine treatment prolonged the time 
course of the inhibitory action on phencyclidine-induced hyperlocomotion
Figure 4 shows the time course (measured in 5-min blocks for the 
60-min period after phencyclidine injection) of the effects of halo-
peridol and clozapine treatment on phencyclidine-induced hyper-
locomotion on the first and last day of drug testing (excluding the 
vehicle + vehicle group). It appears that with repeated treatment, 
haloperidol and clozapine advanced or prolonged their inhibition 
on phencyclidine-induced hyperlocomotion. For example, on day 1, 
the inhibitory effect of haloperidol 0.10 mg/kg started at the 20-min 
point after the phencyclidine injection, and lasted for the remainder 
of the test session (all Ps < 0.05 in comparison to the vehicle + phen-
cyclidine group except at the 25-min point Ps < 0.05). On day 5, its 
inhibitory effect started at the 10-min point (P = 0.008), and lasted for 
the remainder of the test session (all Ps < 0.001 in comparison to the 
vehicle + phencyclidine group except at the 10-min point P = 0.008). 
Similarly for clozapine, on day 1, clozapine 5.0 mg/kg inhibited 
the phencyclidine-induced hyperlocomotion starting at the 20-min 
point (P < 0.05), and lasted for the remainder of the test session (all 
Ps < 0.05). On day 5, clozapine 5 mg/kg inhibited the phencyclidine-
induced hyperlocomotion starting at the 10-min point, and lasted for 
the remainder of the test session (all Ps < 0.001).
3.3. Experiment 3: effects of repeated olanzapine and chlordiazepoxide treat-
ment on amphetamine or phencyclidine-induced hyperlocomotion
3.3.1. Acute olanzapine and chlordiazepoxide treatment inhibited the 
hyperlocomotion induced by amphetamine, but only olanzapine inhibited 
the hyperlocomotion induced by phencyclidine
Figure 5 shows the mean locomotor activity of the seven groups 
of rats during the 60-min period after amphetamine (Figure 5A) or 
phencyclidine (Figure 5B) injection across the five test days. On day 
1, one-way ANOVA analysis revealed a significant main effect of 
“Treatment” (F(2,20) = 12.237, P < 0.001). Post-hoc Tukey tests showed 
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amine-induced hyperlocomotion throughout five test days (Post-
hoc Tukey two-group comparisons: olanzapine vs. amphetamine, P 
< 0.001, chlordiazepoxide vs. amphetamine, P < 0.001). Although the 
effect of olanzapine persisted throughout the 5 test days, it should 
be noted that the average inhibition of olanzapine on amphetamine-
induced hyperlocomotion decreased from 45.5% on day 1 to 29.9% 
on day 5 (Figure 6E). In contrast, the effect of chlordiazepoxide on 
amphetamine-induced hyperlocomotion was relatively stable. Two-
way repeated measures ANOVA on the data from the chlordiazep-
oxide rats revealed no significant main effectof “Days” (F(4,24) = 0.410, 
P = 0.800). For the phencyclidine-induced hyperlocomotion, two-
way repeated measures ANOVA showed a significant main effect 
of “Treatment” (F(2,18) = 8.921, P = 0.002), a significant main effect of 
“Days” (F(4,72) = 4.218, P = 0.004), and “Treatment” × “Days” inter-
action (F(8,72) = 2.958, P = 0.006). Inspection of Figure 6E and F sug-
gests that repeated treatment of olanzapine potentiated inhibition 
on phencyclidine-induced hyperlocomotion across the 5 test days as 
the per cent inhibition changed from 31% on day 1 to 53% on day 5, 
whereas chlordiazepoxide tended to lose its inhibition (19% on day 
1, and 9% on day 5).
To better understand the behavioral patterns of all the drugs 
tested in this study on amphetamine and phencyclidine-induced 
hyperlocomotion, we summarized the results from all three exper-
iments and used the per cent inhibition on each day as a measure 
of a drug's efficacy. As can be seen in Figure 6, with repeated treat-
ment, haloperidol, clozapine and olanzapine all gradually lost their 
ability to inhibit amphetamine-induced hyperlocomotion as there 
was a steady decrease in % inhibition, whereas their ability to inhibit 
phencyclidine-induced hyperlocomotion progressively increased 
across sessions (Figure 6A-E). In contrast, chlordiazepoxide (Fig-
ure 6F) exhibits no impact on phencyclidine-induced hyperloco-
motion. Figure 7 shows the per cent inhibition changes from day 1 
to day 5 for all antipsychotics tested in this study. On day 1, halo-
peridol and olanzapine show a higher efficacy in inhibiting amphet-
amine-induced hyperlocomotion than phencyclidine-induced one, 
whereas clozapine shows the opposite effect. Clozapine is more effi-
cacious in inhibiting phencyclidine-induced hyperlocomotion than 
amphetamine-induced one (Figure 7). However, on day 5, all three 
drugs had a higher per cent inhibition on phencyclidine-induced 
hyperlocomotion than on amphetamine-induced hyperlocomotion. 
This change was due to an increase of per cent inhibition on phen-
cyclidine-induced hyperlocomotion and a decrease of inhibition on 
amphetamine-induced hyperlocomotion from day 1 to day 5.
4. Discussion
Using two well-established hyperlocomotion models, we exam-
ined and compared the effects of repeated antipsychotic treatment 
on hyperlocomotion induced by repeated amphetamine and phen-
cyclidine treatment in an attempt to develop clinically relevant ani-
mal models of antipsychotic drugs that can capture the time course 
of antipsychotic action, e.g., an early-onset and progressively 
increased effect over time. Results show that both typical (halo-
peridol) and atypical (clozapine, olanzapine) antipsychotics acutely 
inhibited phencyclidine-induced hyperlocomotion and progres-
sively enhanced this inhibitory effect over the repeated treatment 
period. In contrast, an anxiolytic drug chlordiazepoxide did not 
show this pattern of action. Repeated chlordiazepoxide treatment 
gradually attenuated its inhibition on phencyclidine-induced hyper-
locomotion. Although antipsychotic drugs also acutely inhibited 
amphetamine-induced hyperlocomotion, so did chlordiazepoxide, 
thus it is impossible to distinguish antipsychotics from chloridiaz-
epoxide on the basis of this action. In addition, repeated antipsy-
chotic treatments gradually lost their inhibition on amphetamine-
induced hyperlocomotion. Based on these findings, we suggest that 
the repeated phencyclidine-induced hyperlocomotion model may 
be better than the repeated amphetamine model in detecting antip-
sychotic action, capturing the time course of antipsychotic effect and 
differentiating antipsychotics from anxiolytics.
hyperlocomotion induced by amphetamine, as there was a signif-
icant group difference between the amphetamine and olanzapine 
group (P < 0.001) and between the amphetamine and chlordiazepox-
ide group (P = 0.006). On phencyclidine-induced hyperlocomotion, 
one-way ANOVA revealed a significant main effect of “Treatment” 
(F(2,20) = 4.111, P = 0.034). Post-hoc Tukey tests showed that in com-
parison to the vehicle treatment, phencyclidine produced a robust 
increase in motor activity (P < 0.001). Our data also showed that only 
olanzapine significantly attenuated the acute effect of phencyclidine, 
as indicated by the finding that only the olanzapine group signif-
icantly differed from the phencyclidine group (P = 0.027), but the 
chlordiazepoxide group did not (P = 0.229).
3.3.2. Repeated olanzapine, but not chlordiazepoxide treatment attenuated 
inhibition on amphetamine-induced hyperlocomotion across days, but sig-
nificantly potentiated inhibition on phencyclidine-induced hyperlocomotion
For amphetamine-induced hyperlocomotion, two-way repeated 
measures ANOVAs with treatment conditions (e.g. vehicle, olanzap-
ine or chlordiazepoxide) as the between-subjects variable and test 
days as the within-subjects variable revealed a significant main effect 
of “Days” (F(4,72) = 3.139, P = 0.019) and a significant main effect of 
“Treatment” (F(2,18) = 22.052, P < 0.001), but no significant “Treatment” 
× “Days” interaction (F(8,72) = 0.967, P = 0.469). Repeated treatment 
of olanzapine and chlordiazepoxide significantly inhibited amphet-
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Shannon, 1997; Millan et al., 1999). Depletion of 5-HT in the nucleus 
accumbens by parachloroamphetamine abolishes phencyclidine-
induced hyperlocomotion (Millan et al., 1999). These findings suggest 
that inhibition of amphetamine-induced hyperlocomotion is primar-
ily mediated by the antagonistic action on dopamine D2 receptors, 
whereas inhibition of phencyclidine-induced hyperlocomotion is 
primarily due to multiple actions of antipsychotics on dopamine D2 
and 5-HT2A receptors, as well as perhaps other molecular sites (Glea-
son and Shannon, 1997; Maurel-Remy et al., 1995; Millan et al., 1999). 
Our results are in agreement with these previous reports except that 
we did not find that acute olanzapine shows a preferential effect on 
phencyclidine-induced hyperlocomotion (Millan et al., 1999). This 
discrepancy may be due to methodological differences such as the 
phencyclidine doses used in these studies. Millan et al. (1999) used 20.0 
mg/kg, whereas we used 3.2 mg/kg. Also, the testing apparatuses 
were different. Millan et al. (1999) used testing chambers equipped 
with 2 infrared beams, whereas we used testing boxes equipped 
with 6 sets of photobeams. Thus, differential effects of typical and 
atypical antipsychotics on amphetamine or phencyclidine-induced 
hyperlocomotion might depend on the specific testing conditions.
In the majority of antipsychotic drug studies using both hyperlo-
comotion models, the effects of antipsychotic drugs and other exper-
imental drugs are often tested after a single injection and efforts 
have been devoted to understanding the neurochemical mecha-
nisms underlying amphetamine and phencyclidine-induced behav-
ioral effects and effects of antipsychotics on both types of hyperloco-
motion. All antipsychotics acutely inhibit motor activation effect of 
amphetamine and phencyclidine (Abekawa et al., 2007; Arnt, 1995; 
Millan et al., 1999, 2008). Antipsychotics with preferential action 
on D2 receptors such as haloperidol, fluphenazine, cis(Z)flupen-
tixol, amisulpride, eticlopride, and raclopride all show a preferential 
inhibitory effect on amphetamine-induced hyperlocomotion over 
phencyclidine-induced one, whereas atypicals such as clozapine and 
olanzapine, which are mixed D2-like/5-HT2A antagonists, have an 
opposite effect, showing a preferential inhibition on phencyclidine-
induced hyperlocomotion (Gleason and Shannon, 1997; Maurel-
Remy et al., 1995; Millan et al., 1999). Other 5-HT2A antagonists such 
as LY53857, ritanserin, ketanserin, fananserin, and MDL100,907, but 
not 5-HT1A or 5-HT3 antagonists such as WAY 100,635 and zatosetron, 
also block phencyclidine-induced hyperlocomotion (Gleason and 
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seen in schizophrenia (Krystal et al., 2005). In the present study, we 
found that only the inhibitory effect of repeated antipsychotic treat-
ment on phencyclidine-induced hyperlocomotion mimics the time 
course of action of antipsychotics in the clinic (e.g. early onset, pro-
gressively increasing) (Agid et al., 2003), suggesting that phency-
clidine-induced hyperlocomotion may be a valid index of schizo-
phrenia-like psychosis. These results also suggest that repeated 
phencyclidine-induced hyperlocomotion model based on a repeated 
antipsychotic treatment regimen is better than amphetamine model 
in mimicking antipsychotic effcts as seen in the clinic. This point is 
particularly important for clozapine, as tolerance, rather than a pro-
gressively enhanced effect (e.g. sensitization) is often observed with 
chronic treatment in animals (Goudie et al., 2007a,b). Thus, many 
researchers have been forced to model this tolerance effect as clo-
zapine’s antipsychotic effect in the clinic, which tends to increase 
over time (Kane et al., 1988; Meltzer et al., 2003). To our best knowl-
edge, inhibition of repeated phencyclidine-induced hyperlocomo-
tion is the only measure that captures the clinical-like pattern of clo-
zapine treatment (e.g. a progressively increased effect); thus, it may 
reflect the “true” antipsychotic action seen in schizophrenic patients. 
In this regard, this model is an important addition to the existing 
animal models based on repeated antipsychotic treatment (Li et al., 
2007), and thus may serve as a valid model to investigate the neu-
rochemical and neural mechanisms of action of antipsychotic drugs 
and search for new antipsycotic drugs with novel mechanisms of 
action.
So then, what mechanism(s) can account for the progressively 
enhanced inhibition of repeated antipsychotic treatment on phen-
cyclidine-induced hyperlocomotion? The mechanism of action of 
phencyclidine is complex (Jentsch and Roth, 1999). Besides block-
ing NMDA receptor channels, phencyclidine can enhance seroton-
ergic, dopaminergic and glutamatergic neurotransmission in the 
nucleus accumbens and prefrontal cortex (Abekawa et al., 2007; 
Maurel-Remy et al., 1995; Millan et al., 1999). Based on the find-
ings that acute 5-HT2A antagonists selectively inhibit phencycli-
dine-induced hyperlocomotion (Gleason and Shannon, 1997), that 
repeated administration of clozapine attenuates phencyclidine-
induced hyperlocomotion even 11 days after the last administra-
tion of clozapine (Abekawa et al., 2007) and causes a down-regula-
tion of 5-HT2A receptors in the prefrontal cortex (Doat-Meyerhoefer 
et al., 2005), as well as the finding that microinjection of phencycli-
dine into the prefrontal cortex elicits hyperlocomotion (Abekawa et 
al., 2007), we speculate that antipsychotics may enhance their inhibi-
tion on phencyclidine-induced hyperlocomotion by down-regulat-
ing 5-HT2A receptors and concomitantly decreasing phencyclidine-
induced dopamine and 5-HT increases in the prefrontal cortex. On 
the other hand, because repeated phencyclidine treatment can also 
induce neurotoxic effects consisting of vacuole formation in pyrami-
dal neurons in several corticolimbic brain regions including the pos-
terior cingulate and retrosplenial cortices (Ellison, 1994; Ellison and 
Switzer, 1993; Olney et al., 1989, 1999), and antipsychotic drugs such 
as haloperidol, clozapine and olanzapine can effectively block the 
neurotoxic action of phencyclidine or MK-801 (Farber et al., 1996, 
1993; Olney and Farber, 1995) and significantly attenuate sensitiza-
tion elicited by phencyclidine (Phillips et al., 2001), thus, one can-
not exclude the possibility that repeated antipsychotic treatment 
may enhance its inhibition on phencyclidine-induced hyperlocomo-
tion by progressively improving its efficacy on prevention of vac-
uole formation in pyramidal neurons in the corticolimbic regions. 
This issue needs further investigation, and the outcome of this line 
of research may shed light on the pathophysiology of schizophrenia 
and the molecular mechanisms responsible for antipsycotic action.
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Although acute amphetamine and phencyclidine hyperlocomo-
tion models are useful in delineating the neurobiological mecha-
nisms of action of psychotherapeutic and psychomimetic drugs, 
they are limited in their ability to capture the intrinsic antipsychotic 
efficacy of a drug and mimic the time course of antipsychotic treat-
ment in the clinic (Agid et al., 2003; Leucht et al., 2005) because inhi-
bition of amphetamine or phencyclidine-induced hyperlocomotion 
is not exclusively the property of antipsychotics (Arnt, 1995; Glea-
son and Shannon, 1997; Millan et al., 1999). In the present study, we 
employed a repeated treatment schedule for both psychotomimetic 
drugs and antipsychotic drugs. We found some interesting effects 
not reported before. First, repeated haloperidol, clozapine, or olan-
zapine treatment all progressively potentiate inhibition on phency-
clidine-induced hyperlocomotion across sessions and prolongs this 
action within sessions, whereas their inhibition on amphetamine-
induced hyperlocomotion is gradually attenuated across sessions 
and shortened within sessions. Second, repeated chlordiazepoxide 
treatment retains its inhibition on amphetamine-induced hyper-
locomotion, and tends to decrease its inhibition on phencyclidine-
induced hyperlocomotion; thus, it shows a behavioral profile dis-
tinct from all antipsychotics. Interestingly, antidepressants such 
as fluoxetine and citalopram also exhibit a behavioral profile dis-
tinctive from that of antipsychotics. Acute fluoxetine or citalopram 
increases amphetamine-induced hyperlocomotion (Fletcher et al., 
2006; Millan et al., 2003) but has no effect on phencyclidine-induced 
model (Redmond et al., 1999). Repeated fluoxetine or citalopram 
treatment tends to enhance amphetamine-induced hyperlocomotion 
(Arnt et al., 1984; Sills et al., 1999, 2000) and phencyclidine-induced 
hyperlocomotion (Redmond et al., 1999). Taken together, a combina-
tion of repeated amphetamine and phencyclidine hyperlocomotion 
models may be utilized to distinguish anxiolytics and antidepres-
sants from antipsychotics.
The present study provides another perspective to evaluate the 
validity of amphetamine versus phencyclidine model as a model 
of schizophrenia. Suggestions have been made that phencyclidine 
model is better than amphetamine model because only NMDA 
antagonists such as ketamine and phencyclidine can induce neu-
rocognitive deficits and negative symptoms in human and ani-
mal subjects resembling those seen in patients with schizophrenia 
(Javitt and Zukin, 1991; Sams-Dodd, 1998). In contrast, patterns of 
symptoms induced by amphetamine differ markedly from those 
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